Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 130,486 |
|
|||||
| News | - | ||||||
| Day High | 7.25 | Low High |
|||||
| Day Low | 6.40 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.17 | 2.66% | 6.57 | 16:07:32 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.46 | 6.40 | 7.25 | 6.57 | 6.40 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,149 | 130,486 | $ 6.74 | $ 880,075 | - | 2.56 - 11.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 1,726 | $ 6.40 | USD |
ESSA Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 290.64M | 44.24M | - | 0 | -26.58M | -0.60 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ESSA Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.32 | 7.60 | 6.18 | 6.53 | 60,869 | -0.75 | -10.25% |
| 1 Month | 9.08 | 9.23 | 6.18 | 7.80 | 60,591 | -2.51 | -27.64% |
| 3 Months | 8.53 | 11.67 | 6.18 | 9.36 | 128,100 | -1.96 | -22.98% |
| 6 Months | 4.04 | 11.67 | 3.80 | 7.33 | 143,741 | 2.53 | 62.62% |
| 1 Year | 2.77 | 11.67 | 2.56 | 6.06 | 107,399 | 3.80 | 137.18% |
| 3 Years | 26.13 | 36.00 | 1.40 | 6.53 | 491,288 | -19.56 | -74.86% |
| 5 Years | 2.46 | 36.00 | 1.40 | 7.62 | 334,146 | 4.11 | 167.07% |
ESSA Pharma Description
| ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |
